Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 15/20 | 0.56 |
| ▸ | NR1H3 | Q13133 | 15/20 | 0.56 |
| ▸ | MLYCD | O95822 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL131990 | 0.87 | NR1H2 (0.68) | NR1H2NR1H3MLYCDSMN1; SMN2 | |
| Water SCHEMBL1684070 | 0.84 | NR1H2 (0.65) | NR1H2NR1H3MLYCDSMN1; SMN2 | |
| SCHEMBL9621271 | 0.79 | NR1H2 (0.60) | NR1H2NR1H3MLYCDSMN1; SMN2 | |
| SCHEMBL24901413 | 0.79 | NR1H2 (0.61) | NR1H2NR1H3MLYCDSMN1; SMN2 | |
| SCHEMBL12334375 | 0.79 | RORC (0.77) | MLYCDSMN1; SMN2 | |
| SCHEMBL6808538 | 0.77 | ESR1 (0.61) | NR1H2NR1H3MLYCDSMN1; SMN2 | |
| SCHEMBL8021367 | 0.77 | NR1H2 (0.58) | NR1H2NR1H3MLYCDSMN1; SMN2 | |
| SCHEMBL1516045 | 0.77 | ESR1 (0.61) | NR1H2NR1H3MLYCDSMN1; SMN2 | |
| SCHEMBL744449 | 0.76 | HSD11B1 (0.50) | NR1H3 | |
| SCHEMBL10878498 | 0.75 | NR1H2 (0.40) | NR1H2NR1H3MLYCDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076966-A1 | METHOD OF INHIBITING TREM-1 | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-03-19 | — | — | US | disclosed |
| EP-3946349-B1 | SR-1903 FOR THE TREATMENT OF INFLAMMATORY, INNATE IMMUNE RESPONSE OR AUTOIMMUNE DISORDERS | UNIV FLORIDA (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12370193-B2 | Method of inhibiting TREM-1 | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-07-29 | — | — | US | disclosed |
| US-20230277527-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2023-09-07 | — | — | US | disclosed |
| US-20220175765-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2022-06-09 | — | — | US | disclosed |
| WO-2022095971-A1 | SPIRO HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海医药集团股份有限公司 | 2022-05-12 | — | — | WO | disclosed |
| US-20220117965-A1 | METHOD OF INHIBITING TREM-1 | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2022-04-21 | — | — | US | disclosed |
| US-20220106329-A1 | BICYCLIC ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B V (US) | 2022-04-07 | — | — | US | disclosed |
| US-20220106323-A1 | SPIROCYCLIC ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2022-04-07 | — | — | US | disclosed |
| EP-3946349-A1 | METHOD OF INHIBITING TREM-1 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3122721-A1 | ROR-GAMMA MODULATORS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015145371-A1 | ROR-GAMMA MODULATORS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2015-10-01 | — | — | WO | disclosed |
| US-20140187554-A1 | MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-07-03 | — | — | US | disclosed |
| WO-2012158784-A2 | MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR | KAMENECKA THEODORE MARK (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012158784-A2 | MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR | KAMENECKA THEODORE MARK (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2010140483-A1 | FLUORINE-CONTAINING COMPOUND, FLUORINE-CONTAINING POLYMER COMPOUND, RESIST COMPOSITION, TOP COAT COMPOSITION AND PATTERN FORMATION METHOD | セントラル硝子株式会社 (JP) | 2010-12-09 | — | — | WO | disclosed |
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | PFIZER INC | 2010-08-12 | — | — | US | disclosed |
| US-20100197591-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES | PFIZER INC | 2010-08-05 | — | — | US | disclosed |
| WO-2010023317-A1 | NOVEL HEXAFLUORO-2-BIPHENYLISOPROPANOL COMPOUNDS THAT MODULATE LXR-TYPE RECEPTORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF AS MEDICAMENTS IN HUMAN AND VETERINARY MEDICINE AND ALSO IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | DGAT1, DGAT2, MOGAT2 | NR1H2 129/4885NR1H3 137/4885MLYCD 1154/4885 |
| US-20100197591-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES | CDK7, DPYD, DHFR | NR1H2 3252/4885NR1H3 3274/4885MLYCD 2909/4885 |
| US-20230277527-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | NR1H2 12/4885NR1H3 18/4885MLYCD 4417/4885 |
| US-20140187554-A1 | MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR | RORB, RORA, RORC | NR1H2 4/4885NR1H3 5/4885MLYCD 2850/4885 |
| US-12370193-B2 | Method of inhibiting TREM-1 | DAPK3, DAPK1, GPR3 | NR1H2 188/4885NR1H3 119/4885MLYCD 3807/4885 |
| US-20260076966-A1 | METHOD OF INHIBITING TREM-1 | NR5A1, NR3C1, NR1H3 | NR1H2 7/4885NR1H3 3/4885MLYCD 4686/4885 |
| US-20220175765-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | NR1H2 12/4885NR1H3 18/4885MLYCD 4417/4885 |
| US-20220117965-A1 | METHOD OF INHIBITING TREM-1 | DAPK3, DAPK1, GPR3 | NR1H2 188/4885NR1H3 119/4885MLYCD 3807/4885 |
| US-20220106323-A1 | SPIROCYCLIC ROR-GAMMA MODULATORS | RORA, RORC, RORB | NR1H2 11/4885NR1H3 13/4885MLYCD 4092/4885 |
| US-20220106329-A1 | BICYCLIC ROR-GAMMA MODULATORS | RORA, RORC, RORB | NR1H2 11/4885NR1H3 14/4885MLYCD 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.